Xie O, et al. - Researchers aimed at ascertaining the epidemiology, treatment and outcomes of vancomycin-resistant enterococcus (VRE) bloodstream infections (BSI) in a vanB predominant setting in malignant hematology and oncology patients. They performed a retrospective review, spanning a 6-year period (2008–2014), at two large Australian centers. In this vanB endemic setting, VRE BSI occurred in the context of substantive prior antibiotic use and was linked with high 30-day mortality. They observed overall, 106 BSI episodes in 96 patients, predominantly Enterococcus faecium vanB (105/106, 99%). Teicoplanin (59), linezolid (6), daptomycin (2) and sequential/multiple agents (21) were provided as treatment. Mortality of 31% was reported at 30-days. On multivariable analysis, teicoplanin was not associated with mortality at 30 days.